Adult stem cells in neural repair: Current options, limitations and perspectives

Table 1 Adult stem cells transplantations: Published clinical trials from the past 4 years

Ref.	Year	No. of patients	Age range	Type of cell grafted	Adjuvant treatments	Follow-up
Dai et al[53]	2013	20	22-54 yr	MSCs	-	6 mo
García-Santos et al[54]	2013	11	33-61 yr	MSCs	-	12 mo
Tian et al[55]	2013	97	21.1-38.21 yr	MSCs	-	14 d
Frolov et al[56]	2012	20	18-55 yr	HSCs	-	48 mo
Karamouzian et al[20]	2012	31	10-50 yr	BMCs	-	33 mo
Martínez et al[57]	2012	67	49.2 ± 10.31 yr	CD133+	-	12 mo
Mazzini et al[28]	2012	19	20-75 yr	MSCs	-	108 mo
Moviglia et al[47]	2012	7	33-78 yr	NSCs	T-cell vaccine	12 mo
Prasad et al[58]	2012	11	30-70 yr	MNCs	-	52 wk
Brazzini et al[59]	2010	53	38-81 yr	BMCs	-	1-18 mo
Karussis et al[26]	2010	19	53.01 yr	MSCs	-	25 mo
Lee et al[60]	2010	16	64.0 ± 11.61 yr	MSCs	-	5 yr
Venkataramana et al[61]	2010	7	22-62 yr	MSCs	-	12-36 mo

¹The authors only provide mean values. MSCs: Mesenchymal stem cells; HSCs: Hematopoietic stem cells; BMCs: Bone marrow stem cells; NSCs: Neural stem cells; MNCs: Mononuclear cells from bone marrow.